Angiotensin II (Ang II) is a newly discovered modulator of intestinal motility, mainly via activation ofexcitatory AT1 receptors (AT1R). We demonstrated that during gut inflammation there is a recruitment ofinhibitory AT2 receptors (AT2R) which would counteract the AT1R-induced effects. Our objective was toexplore the consequence of AT2R activation in the pathogenesis of experimental colitis.Colitis was induced in rats by intrarectal administration of 2,4-Dinitrobenzene sulfonic acid (DNBS).Colonic damage was assessed by macro- and microscopic scores, myeloperoxidase activity andinflammatory cytokine expression on day 6 after colitis induction. Colonic contractility was recorded invitro. In a separate group of animals, the effects of 6-day intraperitoneal treatment with PD123319 (3 mg/kg)on colitis features were examined.Colon from DNBS-rats showed marked inflammation associated to a decrease of spontaneous and evokedmechanical activity. Ang II contractile response was reduced by the activation of inhibitory AT2 receptors.PD123319, AT2R antagonist, per se ameliorated colonic contractility. Inhibition of nitric oxide synthase orneural activity induced as well an increase of contractility in DNBS preparations. In such conditionsPD123319 did not induce further effects. In DNBS rats daily i.p. treatment with PD123319, attenuated colitisseverity, reducing body weight loss and incidence of diarrhoea and improving mechanical activity in vitro.In conclusion, during inflammation constitutively activated AT2 receptors via involvement of enteric nervesand NO would contribute to the reduction of muscle contractility. Blocking AT2R activation in vivo seemsto improve some symptoms during intestinal inflammation, driving future study.
|Number of pages||1|
|Publication status||Published - 2016|